This open label clinical study provides updated evaluation of the strategy of single unit cord blood transplants (CBTs) with co-infusion of third-party donor (TPD) mobilized hematopoietic stem cells (MHSC). Fifty-five adults with high-risk hematological malignancies, median age 34 years (16-60 years) and weight 70 kg (43-95 kg), received CBTs (median 2.39 Â 10 7 total nucleated cell (TNC) per kg and 0.11 Â 10 6 CD34 þ per kg) and TPD-MHSC (median 2.4 Â 106 CD34 þ per kg and 3.2 Â 10 3 CD3 þ per kg). Median time to ANC and to CB-ANC 40.5 Â 10 9 /l as well as to full CB-chimerism was 10, 21 and 44 days, with maximum cumulative incidences (MCI) of 0.96, 0.95 and 0.91. Median time to unsupported platelets 420 Â 10 9 /l was 32 days (MCI 0.78). MCI for grades I-IV and III-IV acute GVHD (aGVHD) were 0.62 and 0.11; 12 of 41 patients (29%) who are at risk developed chronic GVHD, becoming severely extensive in three patients. Relapses occurred in seven patients (MCI ¼ 0.17). The main causes of morbi-mortality were post-engraftment infections. CMV reactivations were the most frequent, their incidence declining after the fourth month. Five-year overall survival and disease-free survival (Kaplan-Meier) were 56 % and 47% (63% and 54% for patients p40 years). In conclusion, CBT with single units of relatively low cell content and 0-3 HLA mismatches is feasible as a first choice option for adult patients who lack a readily available adequate adult donor.
Introduction
Late engraftment and low rate of engraftment are a major drawback for single unit cord blood transplants (CBTs) in adults after myeloablative conditioning. This limitation may be overcome by the co-infusion of a relatively low number of T-cell-depleted mobilized hematopoietic stem cells (MHSC) from a third-party donor (TPD). [1] [2] [3] Here we report results of engraftment, morbidity and survival of a total of 55 consecutive patients transplanted in our center using this strategy between March 1999 and October 2007. These data confirm and extend results reported previously on the value of the procedure to achieve high rates of engraftment and full chimerism of single unit CBT in adults after myeloablative conditioning. 3 
Design and methods

Design
This was an open label non-randomized observational clinical study.
Regulatory requirements
The clinical protocol was approved by the Institutional Research and Ethics Committee for treatment of adult patients with high-risk hematological conditions. Written informed consent, in accordance with the Helsinki Declaration, was obtained from all patients or their legal guardians.
Patient eligibility, HLA typing and procurement of transplantation products All these were as described earlier. 3 In brief, patients were eligible for enrollment if they were older than 15 years and had a high relapse-risk hematologic neoplasm, including CML beyond the initial chronic phase; acute leukemia (AL) beyond first remission, with high-risk cytogenetics or poor response to induction chemotherapy; severe myelodysplasia; and highgrade lymphomas with poor response to chemotherapy.
Preparative regimen, GVHD prophylaxis and supportive care
The preparative regimen has been described earlier. 3 First three patients received fractionated TBI at a dose of 12 Gy given in six 0.2 doses (lungs shielded at 8 Gy) ), i.v. CY 120 mg/kg total dose (60 mg/kg/day over 1 h, days À3 and À2) and antithymocyte globulin (ATG). 3 Thirty-seven patients received TBI at a total dose of 10 Gy in five 2 Gy fractions in 3 days (À8 to À6) with lungs also shielded at 8 Gy, i.v. fludarabine, total dose of 120 mg/m 2 (30 mg/m 2 / day, days À5 to À2) and the same doses of CY and ATG. To reduce post-transplant immune deficiency, ATG was omitted in the first two patients and after severe GVHD occurred in one patient, it was maintained in all remaining patients. Up to 2000, equine ATG (Linfoglobulina, Lyon, France; Imtix, Lyon, France; Sangstat, Lyon, France) was given at 30 mg/kg on day À1 and thereafter rabbit ATG (Timoglobulina, Marcy L'etoile, France; Genzyme, Marcy L'etoile, France) 2 mg/kg on days À2 and À1. BU was substituted for TBI when this was not indicated (14 patients): up to 2006, oral BU was given at 4 mg/kg/day on days À5 and À4; from 2006 onward, Busilvex (PierreFabre, Boulogne, France) was given i.v. instead (twice daily 3.2 mg/kg doses). Two patients in an unstable remission of a high-grade non-Hodgkin's lymphoma had Ara-C (2000 mg/ m 2 /day Â 5 days) added to their conditioning regimen. All patients received granulocyte-colony stimulating factor (G-CSF) (Neupogen, Amgen, Breda, The Netherlands) that was started after the transplant at a dose of 30 MU daily and continued until a sustained ANC higher than 1 Â 10 9 /l was reached. The dose was then adjusted as required to maintain ANC above this level.
For GVHD prophylaxis, CsA was begun i.v. on day À5 at a dose of 3 mg/kg daily and adjusted to a serum level of 180-250 ng/ml. It was administered through the oral route as soon as oral tolerance developed, and was continued until full CB engraftment was achieved, at which point tapering was immediately initiated if there were no signs of GVHD. Methylprednisolone was given i.v. at a dose of 1 mg/kg/day from day À2 to days þ 10 to þ 14, and was rapidly tapered thereafter unless there was clinical indication for its maintenance. Corticosteroid-based treatment (methylprednisolone 1-2 mg/kg/day) was given when grade II or higher acute GVHD (aGVHD) developed.
Patients were nursed in positive pressure air-filtered rooms and had gut decontamination using ciprofloxacin initiated on day À8, which was continued until ANC dropped below 0.5 Â 10 9 /l, and then patients were switched to i.v. meropenem. They also received daily i.v. trimethoprim-sulfamethoxazole (from days À8 to À2), i.v. fluconazole (from day À8 until ANC recovery) and i.v. immunoglobulin (400 mg/kg weekly from days À3 to þ 60). For antiviral prophylaxis, patients received i.v. gancyclovir (days À8 to À1) and then acyclovir from day 0 up to 1 year. Beginning in 2004, chemoprophylaxis for toxoplasmosis was given to seropositive patients and to those seronegative patients who were receiving MHSC from a seropositive TPD. This consisted of oral azithromycin 1 g twice a week until CB engraftment, and then pirimetamine-sulfadioxine (Fansidar, Nutley, NJ, USA) and folic acid continued until day þ 180. 4 Post-transplant prophylaxis for Pneumocistis carinii infection with trimethoprim-sulfamethoxazole was used in all patients except those receiving prophylaxis for toxoplasmosis with Fansidar. Transfusion support and treatments for infection protocols were as usual for patients receiving hematopoietic stem cell (HSC) transplants. 2 Definitions and assessments of hematopoietic recovery, chimerism and transplant-related events All these were as reported earlier. 3 Hematological recovery was assessed on the basis of peripheral blood ANC, platelet count and transfusion requirements. Time to granulocyte recovery was defined as the interval to the first of a minimum of three consecutive days with ANC40.5 Â 10 9 /l and time to platelet recovery, as the interval to the first day of platelet counts 420 Â 10 9 /l or 450 Â 10 9 /l without transfusion support for a minimum of one week. Engraftment failure was defined as the absence of durable ANC recovery at day þ 30 in surviving patients. Chimerism was evaluated in BM and/or peripheral blood cells (granulocytes and mononuclear cells) at least once a week from day þ 7 until day þ 28 and thereafter one to two times a month. This was carried out using HLA allele analysis using the RSCA (reference strand mediated conformation analysis) method and/or by quantitative molecular genotype analysis using 15 markers of DNA STR (short tandem repeat) tagged with four fluorochromes and analyzed by ABI PRISM 3100 sequencer and the Gene Mapper 3.0 software. 5, 6 This method was also used to analyze DNA from biopsy material taken from GVHD skin lesions to evaluate the presence of donor cells.
Time to CB engraftment was defined as the time to sustained ANC of CB origin (CB-ANC)40.5 Â 10 9 /l. This was determined as a function of the total ANC and the percentage of CB DNA determined by the above-mentioned methods in the DNA obtained from granulocytes after the transplant.
Acute GVHD was graded 0 to IV and chronic GVHD as limited or extensive according to established criteria. TRM was defined as death from any cause except relapse or unrelated factors. Relapse was defined as the evidence of disease in peripheral blood, marrow or extra-medullar sites by morphological or, when applicable, cytogenetic or molecular criteria.
Statistical analyses
Cumulative incidences of hematopoietic recovery, TRM and relapse were estimated by competing risk analysis. 7 Hematopoietic recovery was considered as a censored observation, whereas death and relapse before hematopoietic recovery were regarded as competing events. For the analysis of mortality, TRM and relapse were considered as competing risks. The Mann-Whitney non-parametric U-test was used to compare time to engraftment. Overall survival and disease-free survival were estimated by the Kaplan-Meier method.
Results
Characteristics of patients
Characteristics of the patients, including demographics, pre-transplant serologies, diagnosis and added risk factors, are shown in Table 1 . Eight of the 41 patients with AL were in PR. Two of the four patients with CML were in accelerated phase, one patient was in second chronic phase and one patient had had an earlier autotransplant. Three of the five non-Hodgkin's lymphoma patients were in unstable remission.
Transplanted cord blood units The units were provided by different CB banks of the international network. Cellularity and compatibility data of the transplanted units are shown in Table 2 .
HLA mismatches were 0-3 (median 2) for class I A and B loci (serologic) and class II DRB1 (allelic), both GVHD and rejection wise. Infused TNC (post-thawing counts) ranged from 1.14 to 4.50 Â 10 7 /kg (median 2.39) and the units pre-freezing counts of CD34 þ cells, ranged from 0.035 to 0.37 Â 10 6 /kg (median 0.11).
Third-party donor cells
The TPD was haploidentical in 38 instances, and in 17 instances the donor (related or unrelated) did not share a haplotype (Table 3 ). The number of infused TPD-MHSC (selected as CD34 þ and/or CD133 þ ) ranged from 1.05 to 3.34 Â 10 6 /kg (median 2.40) with a median purity of 98.2% (90-99.7%), and the number of infused CD3 þ cells was 0.5-15.6 Â 10 3 /kg (median 3.2).
Hematopoietic recovery and engraftment
Follow-up ranged from 1 to 108 months (median 13), with 33 patients alive at study closure (December 2007; Table 4 ). The median follow-up time of the 33 patients who were alive was 28 months, with 20 patients (61%) surviving more than 24 months.
Data on cumulative incidence of granulocyte recovery, CB engraftment, full CB chimerism and platelet recovery are graphically shown in Figure 1 . Sequential evaluation of chimerism showed initial predominance of TPD DNA both in granulocytes and mononuclear circulating and marrow cells, followed by progressive replacement by cells from the CB transplant.
3 Time to ANC40.5 Â 10 9 /l ranged from 9 to 36 days (P 50 ¼ 10 and P 95 ¼ 31) with maximum cumulative incidence (MCI) of 0.96 (95% confidence interval (CI): 0.91-1.00) The estimated time to CB-ANC40.5 Â 10 9 /l ranged from 12 to 57 days (P 50 ¼ 21, P 95 ¼ 57 and MCI ¼ 0.95, 95% CI: 0.89-1.00). Final full CB chimerism was achieved by 50 patients, which /l and 50 Â 10 9 /l were 32 and 57 days, with MCI of 0.78 (95% CI: 0.68-0.90) and 0.69 (95% CI: 0.58-0.82).
One heavily pre-treated patient had graft failure seemingly related to heavy marrow stromal damage. In three other patients, the initially transplanted CB unit failed to engraft. This was due to lack of viable hematopoietic progenitors in the thawed CB unit in two patients and to early rejection in one patient. These three patients received a second CB unit 32, 34 and 63 days after the initial one. In the interim, hematopoiesis was maintained by the TPD. For these cases, data entered in table 4 as time for CB engraftment are those of the second transplanted unit. No significant correlations were observed between the number of CB TNC or CD34 þ cells per kg of the transplanted CB units and times to CB-ANC40.5 Â 10 9 /l and to full CB chimerism.
Clinical effects related to immune recovery, morbidity, mortality and survival Thirty-four patients had manifestations of aGVHD of any grade initiated after 11-105 (median 30) days from the transplant; grades II-IV were seen in 10 patients, and grades III-IV in six patients (MCI: 0.63, 0.28 and 0.11, respectively; Figure 2 ). DNA analysis of skin biopsy material of grades II-IV aGVHD lesions from 11 patients detected CB DNA in five patients, but in no case was TPD-DNA detected. There were three deaths primarily related to aGVHD. One of these occurred in one of the two patients who had not received ATG as part of the preparative regimen. In another two patients, aGVHD was refractory to corticosteroids and resolved after infusions of MSC obtained from the TPD. All the others responded to treatment with corticosteroid therapy. Twelve of 41 at-risk patients (29.3%) developed manifestations of cGVHD, which was limited in all but three patients, and caused death in one patient. These data compare favorably with other HSC transplant procedures.
Relapses have occurred in seven patients, resulting in a 5-year cumulative incidence of 0.17 (95% CI: 0.08-0.35) for Figure 2) . Three of these patients died and four remained alive under chemotherapy (two Ph1 þ in CR receiving tyrosine kinase inhibitors) at study closure. Post-engraftment opportunistic infections were a major cause of morbidity and the cause of death of eight patients. The most frequent were CMV reactivations, with a total of 54 episodes documented; incidence began declining by the fourth month (Figure 3) . In seven instances, these resulted in CMV disease, causing four deaths. There were also 10 cases of hemorrhagic cystitis related to polyoma virus (all within the first 3 months and none causing death). Conversion to HBVsAg þ occurred in 4 of 11 patients previously HbVsAg-/HBVsAb þ /HBVcAb þ . All these patients are in good health after antiviral treatment. One patient developed EBV lymphoproliferative disease that was the cause her death. Development of Toxoplasma infection in four patients, causing death in one patient, prompted us to introduce chemoprophylaxis for this agent. No new cases of Toxoplasma infection were observed thereafter.
Altogether, there were 22 deaths, 3 due to relapse and 19 related to the transplant procedure (TRM): six toxic, four due to GVHD, eight due to opportunistic infections and one due to graft failure. The Kaplan-Meier survival curves are shown in Figure 4 . For the entire group, overall 5-year survival was 56% (41% for patients older than 40 and 63% for the younger patients; P ¼ 0.04) and disease-free survival was 47% (34% for the older patients and 61% for the younger patients; P ¼ 0.06; Table 5 ). Dual CB/TPD-MHSC transplants G Bautista et al
Discussion
Cord blood transplantation is an option for patients with hematologic malignancies who lack a readily available related or unrelated volunteer donor with adequate HLA compatibility, because of its well-recognized tolerance of HLA mismatches with relatively low incidence and severity of GVHD, substantial antitumor effect (GVL) and fast accessibility. [8] [9] [10] In addition, several registry and single institution studies have shown, both for children and adults, overall and disease-free survival rates similar to other allogeneic HSC transplants, although with different causes of mortality. [11] [12] [13] [14] [15] [16] [17] [18] Slow and low rate of engraftment, infections during lengthy post-transplant neutropenia and toxicity of preparative regimens were recognized as factors for early TRM of CBT in large registry-based observational studies. [13] [14] Low cell content in the transplanted product and higher degree of HLA incompatibility are, in turn, the main factors for graft failure and late engraftment. 19, 20 All of these factors have jeopardized its wider use, especially for adults. Another concern with CBT relates to the Patients at risk
CMV reactivations
Months after transplant Figure 3 Incidence of CMV reactivations. The declining incidence of CMV reactivations is a reliable biological marker of the development of some degree of protective immunity against viral agents by recipients of CB transplants. 
Table 5
Post-transplant complications and survival data Acute GVHD n (%).
Evaluable patients 55
Grade: 0 21 (38. Dual CB/TPD-MHSC transplants G Bautista et al possibility of poor development of antitumor and protective immunity against pathogens. Obviously, a high rate of engraftment is a necessary prerequisite for an adequate evaluation of the CBT immune-related matters of cGVHD, graft versus tumor effects (GVT) and protective immunity. Strategies that are being pursued to obtain high rates of engraftment include, among others, ex vivo expansion of HSC of an aliquot of the transplanted CB, intraosseous infusion, infusion of two CB units and the co-infusion of TPD MHSC proposed by our group. Our results confirm the value of the strategy that we described earlier of supporting the single unit CBTs after myeloablative conditioning of reduced extra-hematological toxicity by the infusion of highly T-cell-depleted MHSC from a TPD. 3 This approach allows the use of units of cell content lower than the often referred minimal thresholds of 2.5 Â 10 7 per kg TNC and 0.17 Â 10 6 per kg CD34 þ cells, as required for high probability of engraftment, 20, 21 which is especially convenient for adult patients who represent the largest part of the demand for HSC transplants. Units of relatively low cell content and 0-3 HLA disparities very often are the only ones available for adult patients in the international network of CB banks at the present time.
The CB-TNC received by our patients (post-thaw counts) ranged from 1.14 to 4.50 Â 10 7 /kg (median 2.39), with 1-2/6 HLA disparities and ANC4500 Â 10 9 /l promptly recovered in most patients (P 50 ¼ 10 and P 95 ¼ 31 days) followed by recovery of CB-ANC4500 Â 10 9 /l after intervals equivalent to those observed in single unit CBT without TPD-MHSC support (P 50 ¼ 21 and P 95 ¼ 57 days). Full CB chimerism was also achieved by most patients within 100 days (P 50 ¼ 44 and P 90 ¼ 97 days), after a transient period of complete double CB/TPD chimerism. Recovery of CB-ANC40.5 Â 10 9 /l basically reflects the engraftment potential of the CBT. Meanwhile, achievement of final full CB chimerism is, in this model of dual CB/TPD-MHSC transplant, dependent not only on CB engraftment but also on the loss of the TPD graft, whatever its mechanism. Moreover, the 'bridge graft' of the TPD cells that results from the procedure furnishes safety and time for a second CBT in case of failure of the initial one, either because of poor quality of the thawed product or other possible causes. This was the case in three of our patients who obtained engraftment and full CB chimerism from a second CBT given 32, 34 and 63 days after failing the initial one. In the interim, all three patients maintained a normal ANC from the TPD. It is conceivable that less intense conditioning regimens could be feasible without jeopardizing these results on engraftment.
The number of TPD cells given was chosen with the aim of giving HSC cells with no more than 10 4 per kg contaminating CD3 þ cells. Because of poor yield of the selection procedure, one patient received 1.56 Â 10 4 per kg CD3 þ cells from the TPD without any adverse effects observed. No clinically relevant differences resulted from the use of TPD MHSC selected as CD34 þ or CD133 þ cells. There were no differences either between the engraftment of the TPD with and without shared haplotype, except for the lack of engraftment that occurred in the four patients who received TPD cells from their mothers, which did not relate to non-inherited maternal HLA antigens. 3 According to published reports, for most patients the time to ANC recovery after double CBT, both with standard and reduced-intensity conditioning, is not significantly shorter than that for single unit CBT and usually results from the exclusive and unpredictable engraftment of one of the units. [22] [23] [24] [25] The benefit of double CBT seems to result from a higher chance for engraftment and full CB chimerism, on top of other possible undetermined effects, immunological or otherwise, that could also influence the prevalence of the engrafting unit. We do not have data indicative of the mechanism underlying the final replacement of the TPD graft by the CBT in the dual CBT/TPD-MHSC model. A higher proliferative potential of the CB HSCs and rejection of the TPD by the CBT-derived immune system could be the contributing factors.
The minimum cell content required for low risk of graft failure after single unit CBT has been estimated differently by different authors. 20, 21 To a certain extent, this reflects the use of different criteria to evaluate cellularity of the transplanted CB units. 26, 27 Transplant centers make their choices of use of the CB units on the basis of the data reported by the CB banks, usually pre-freezing counts. Consequently, it is necessary that thresholds of minimal cell requirements for low risk of engraftment failure be clearly defined in terms of the data that appear in the CB bank reports, which ideally should include post-thaw data (cell counts, viability and clonogenic capacity) obtained from pilot samples. 28 All this would facilitate decision-making on whether or not to perform single unit CB transplants, thus helping to avoid undue risks for the patient or undue cost overruns either by using double CBT or TPD cells. In this regard, it can be said that in Spain the cost of obtaining the TPD-MHSC is less than one-third the amount charged by CB banks for one unit (h18 000-30 000).
The results of this study using the strategy of dual CB/ TPD-MHSC transplants also showed low incidences of severe GVHD and relapses (suggestive of a valuable GVT effect), as well as high incidence of late post-engraftment opportunistic infections (denoting poor recovery of protective immunity against these pathogens), as is the case for CBT using other strategies. We observed a high incidence of CMV reactivations after the transplant, with a tendency to diminish after about 3 months, a clear indicator of the development of some degree of protective immunity. The underlying pathophysiology of this pattern of immune reconstitution after the CBTs is not well understood. Preliminary results of ongoing studies on immune reconstitution in our patients (data not shown) are indicative of substantial contribution of thymic neogenesis to the recovery of the T cells as well as of the development of specific CMV-specific T cells derived from the CB transplant after CMV reactivations.
The early recovery of the ANC that results from the 'bridge' engraftment of the co-infused TPD-MHSC allows the patients to withstand treatments with gancyclovir and other drugs with myelosuppressive side effects in case these are needed because of infections. However, the most effective therapeutic actions for these complications would obviously be those that could enhance the development of T-cell populations reactive against the responsible pathogens. Nevertheless, it is also conceivable that beneficial effects could result from the infusion of the TPDselected/expanded populations of cells, other than MHSC, that could act on the hematopoietic microenvironment or as immunomodulators. Cells that could provide benefit in terms of GVHD, GVT and antimicrobial immunity might deserve evaluation including MSC, T-regs, natural killer cells and pathogen-specific effector lymphocytes. [29] [30] [31] [32] [33] In summary, the results of this study of dual CB/TPD-MHSC transplant are: (1) short periods of post-transplant neutropenia because of early engraftment of the TPD HSC acting as a 'bridge transplant'; (2) low rates of toxic complications and granulocytopenia-related infections; (3) high rates of CB engraftment and full CB chimerism; (4) incidence of relapses suggestive of valuable GVL effect); (5) low incidence of serious GVHD to which the low incidence of neutropenia-related infections may be a contributing factor; and (6) slow development of protective immunity against viral and other agents.
Conclusions
The strategy of co-infusion of MHSC from a TPD can contribute to making CBTs feasible as a first choice option for a large number of patients of wide age range who lack a related HLA compatible enough donor by reducing the non-hematologic toxic effects of the conditioning regimen as well as the incidence of neutropenia-related infections, thus favoring engraftment. Additional research is needed to further evaluate the possibilities of optimizing posttransplant immune recovery for a better balance between GVT and protection against pathogens versus risk of GVHD. We believe the strategy of dual CB/TPD-MHSC transplant is a valuable tool for the development of all these research actions, deserving evaluation by other groups.
